Jamshidi Abolfazl, Liu Janice, Jadidi Sajedeh, Harland Emily, Moein Mahmoudreza, Saidi Reza
Division of Transplant Services, Department of Surgery, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, 13210, USA.
Int Urol Nephrol. 2025 Jun 6. doi: 10.1007/s11255-025-04585-0.
We aimed to evaluate kidney retransplantation outcomes to optimize patient care and reduce the risk of further retransplantation.
We conducted a retrospective longitudinal analysis of the Scientific Registry of Transplant Recipients (SRTR) database for kidney retransplants performed in the United States from January 2000 to May 2023. Patients were divided into subgroups based on transplant date and number of previous transplants. Outcomes were assessed by patient and allograft survival.
A total of 34,230 patients were evaluated (12,224 in 2000-2011, 22,006 in 2012-2023). The proportion of DCD (donation after cardiac death) donors was significantly higher in 2012-2023 (21.3% vs. 8.8%, p < 0.001). Both patient and allograft survival improved in the more recent time frame (5-year survival: 84.8% vs. 83.7% for patients; 75.9% vs. 69.3% for allografts, p < 0.001). Allograft failure rates were higher with increasing retransplant attempts (5-year survival: 73.4% vs. 71.8% vs. 62.3% for first, second, and third + retransplants, p < 0.001). DGF increased failure risk (HR: 1.69 [1.60-1.79] in 2000-2011; HR: 1.79 [1.63-1.97] in 2012-2023), as did higher kidney donor profile index (KDPI) (HR: 1.96 [1.70-2.26] in 2000-2011; HR: 2.34 [1.82-3.01] in 2012-2023). Allograft thrombosis contribution as an etiology for failure increased (OR: 2.94 [2.20, 3.92] for the first; OR: 3.13 [1.58, 6.79] for the second + retransplants).
Kidney retransplant outcomes have improved, but each successive transplant has a poorer prognosis. Careful patient selection and risk assessment, especially regarding high KDPI and DGF (delayed graft function), are critical. Further investigation is needed into the rising proportion of allograft thrombosis.
我们旨在评估肾再次移植的结果,以优化患者护理并降低再次移植的风险。
我们对美国移植受者科学登记处(SRTR)数据库进行了回顾性纵向分析,该数据库涵盖了2000年1月至2023年5月期间进行的肾再次移植。患者根据移植日期和既往移植次数分为亚组。通过患者和移植肾存活情况评估结果。
共评估了34230例患者(2000 - 2011年有12224例,2012 - 2023年有22006例)。2012 - 2023年心脏死亡后捐赠(DCD)供者的比例显著更高(21.3%对8.8%,p < 0.001)。在最近时间段内,患者和移植肾的存活情况均有所改善(5年生存率:患者为84.8%对83.7%;移植肾为75.9%对69.3%,p < 0.001)。随着再次移植尝试次数增加,移植肾失败率更高(首次、第二次和第三次及以上再次移植的5年生存率分别为73.4%、71.8%和62.3%,p < 0.001)。移植肾功能延迟(DGF)增加了失败风险(2000 - 2011年风险比[HR]:1.69[1.60 - 1.79];2012 - 2023年HR:1.79[1.63 - 1.97]),较高的肾脏供者特征指数(KDPI)也是如此(2000 - 2011年HR:1.96[1.70 - 2.26];2012 - 2023年HR:2.34[1.82 - 3.01])。移植肾血栓形成作为失败病因的比例增加(首次移植的比值比[OR]:2.94[2.20, 3.92];第二次及以上再次移植的OR:3.13[1.58, 6.79])。
肾再次移植结果有所改善,但每次连续移植的预后更差。仔细的患者选择和风险评估,特别是关于高KDPI和DGF(移植肾功能延迟),至关重要。需要对移植肾血栓形成比例上升进行进一步研究。